CardioMetabolic Disease Research

Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of potential innovative medicines for obesity, kidney and liver diseases – including non-alcoholic steatohepatitis (NASH).